For example, mAbs targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) control cholesterol metabolism, whereas anti-IL-1β mAbs aid in decreasing inflammation and minimizing the risk of recurring events in patients with prior myocardial infarctions. This evidence concerns the gene PCSK9 and myocardial infarction.